Uberla K - Search Results

1

Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors.

Walter H, Schmidt B, Korn K, Vandamme AM, Harrer T, Uberla K. Walter H, et al. Among authors: uberla k. J Clin Virol. 1999 Jun;13(1-2):71-80. doi: 10.1016/s1386-6532(99)00010-4. J Clin Virol. 1999. PMID: 10405894

2

Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors.

Uberla K, Stahl-Hennig C, Böttiger D, Mätz-Rensing K, Kaup FJ, Li J, Haseltine WA, Fleckenstein B, Hunsmann G, Oberg B, et al. Uberla K, et al. Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8210-4. doi: 10.1073/pnas.92.18.8210. Proc Natl Acad Sci U S A. 1995. PMID: 7545297 Free PMC article.

3

Construction, replication, and immunogenic properties of a simian immunodeficiency virus expressing interleukin-2.

Gundlach BR, Linhart H, Dittmer U, Sopper S, Reiprich S, Fuchs D, Fleckenstein B, Hunsmann G, Stahl-Hennig C, Uberla K. Gundlach BR, et al. Among authors: uberla k. J Virol. 1997 Mar;71(3):2225-32. doi: 10.1128/JVI.71.3.2225-2232.1997. J Virol. 1997. PMID: 9032357 Free PMC article.

4

Replication-competent chimeric lenti-oncovirus with expanded host cell tropism.

Reiprich S, Gundlach BR, Fleckenstein B, Uberla K. Reiprich S, et al. Among authors: uberla k. J Virol. 1997 Apr;71(4):3328-31. doi: 10.1128/JVI.71.4.3328-3331.1997. J Virol. 1997. PMID: 9060704 Free PMC article.

5

Simple algorithm derived from a geno-/phenotypic database to predict HIV-1 protease inhibitor resistance.

Schmidt B, Walter H, Moschik B, Paatz C, van Vaerenbergh K, Vandamme AM, Schmitt M, Harrer T, Uberla K, Korn K. Schmidt B, et al. Among authors: uberla k. AIDS. 2000 Aug 18;14(12):1731-8. doi: 10.1097/00002030-200008180-00007. AIDS. 2000. PMID: 10985309

6

Low level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors.

Schmidt B, Korn K, Moschik B, Paatz C, Uberla K, Walter H. Schmidt B, et al. Among authors: uberla k. Antimicrob Agents Chemother. 2000 Nov;44(11):3213-6. doi: 10.1128/AAC.44.11.3213-3216.2000. Antimicrob Agents Chemother. 2000. PMID: 11036057 Free PMC article.

7

Phenotypic HIV-1 resistance correlates with treatment outcome of nelfinavir salvage therapy.

Walter H, Schmidt B, Rascu A, Helm M, Moschik B, Paatz C, Kurowski M, Korn K, Uberla K, Harrer T. Walter H, et al. Among authors: uberla k. Antivir Ther. 2000 Dec;5(4):249-56. Antivir Ther. 2000. PMID: 11142619 Clinical Trial.

8

No evidence for persistence of multidrug-resistant viral strains after a 7-month treatment interruption in an HIV-1-infected individual.

Walter H, Löw P, Harrer T, Schmitt M, Schwingel E, Tschochner M, Helm M, Korn K, Uberla K, Schmidt B. Walter H, et al. Among authors: uberla k. J Acquir Immune Defic Syndr. 2002 Oct 1;31(2):137-46. doi: 10.1097/00126334-200210010-00003. J Acquir Immune Defic Syndr. 2002. PMID: 12394791

9

Characterization of virus isolates by particle-associated nucleic acid PCR.

Stang A, Korn K, Wildner O, Uberla K. Stang A, et al. Among authors: uberla k. J Clin Microbiol. 2005 Feb;43(2):716-20. doi: 10.1128/JCM.43.2.716-720.2005. J Clin Microbiol. 2005. PMID: 15695669 Free PMC article.

10

Clinically significant CMV (re)activation during or after radiotherapy/chemotherapy of the brain : Correlation with neurological deterioration and improvement upon antiviral treatment.

Goerig N, Semrau S, Frey B, Korn K, Fleckenstein B, Überla K, Dörfler A, Putz F, Gaipl US, Fietkau R. Goerig N, et al. Among authors: uberla k. Strahlenther Onkol. 2016 Jul;192(7):489-97. doi: 10.1007/s00066-016-0987-7. Epub 2016 May 31. Strahlenther Onkol. 2016. PMID: 27245820 English.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

289 results

Search Page